Article
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Blood - 29 Nov 2012
Fathi Amir T, Sadrzadeh Hossein, Borger Darrell R, Ballen Karen K, Amrein Philip C, Attar Eyal C, Foster Julia, Burke Meghan, Lopez Hector U, Matulis Christina R, Edmonds Katherine M, Iafrate A John, Straley Kimberly S, Yen Katharine E, Agresta Samuel, Schenkein David P, Hill Cedric, Emadi Ashkan, Neuberg Donna S, Stone Richard M, Chen Yi-Bin
Abstract excerpt
Mutations of genes encoding isocitrate dehydrogenase (IDH1 and IDH2) have been recently described in acute myeloid leukemia (AML). Serum and myeloblast samples from patients with IDH-mutant AML contain high levels of the metabolite 2-hydroxyglutarate (2-HG), a product of the altered IDH protein. In this prospective study, we sought to determine whether 2-HG can potentially serve as a noninvasive biomarker of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.